One dose of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN; Jynneos) mpox vaccine was moderately effective in preventing mpox infections, according to a Canadian observational, emulated ...

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for the prevention of mpox and smallpox in adults, but insufficient data are available to support ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

The agreement, which also covers South Korea, Taiwan and certain markets in Southeast Asia, will see Nuance take the lead on a phase 3 trial of the MVA-BN RSV vaccine in China that will run ...

The announcement came on the heels of the arrival of the first MVA-BN vaccines to the Democratic Republic of Congo (DRC), the epicentre of the epidemic. "This first prequalification of a vaccine ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in ...

Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children two to 11 years of age and has started a Phase II trial to support the approval.

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for the prevention of mpox and smallpox in adults, but insufficient data are available to support ...

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian ...

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A ...